MYCN and neuroblastoma: The International Neuroblastoma Risk Group (INRG) system thus classifies tumors based on a combination of clinical and biological markers such as patient age, histologic category, stage, grade of differentiation, MYCN amplification, chromosome 11q status and DNA ploidy to guide risk-based treatments for patients with NB (3).